['pre-diabetes']
['bti320', 'bti320 matching placebo']

        Inclusion Criteria:

          1. Adult subjects ≥ 18-70 years inclusive

          2. Chinese ethnicity

          3. High risk subject with pre-diabetes as defined by meeting at least 2 of the following
             criteria from (a), (b) and (c):

               1. FPG ≥ 5.6-6.9 mmol/l and/or 2-hour PG ≥ 7.8-11.0 mmol/l during 75 gram OGTT

               2. HbA1c ≥ 5.7-6.4%

               3. At least one of the following risk factors:-

                    -  History of gestational diabetes

                    -  Family history of diabetes in first degree relative

                    -  2 components or more of the metabolic syndrome (triglyceride ≥ 1.7 mmol/L,
                       blood pressure (BP) ≥ 130/80 mmHg, high density-lipoprotein (HDL)
                       cholesterol <1.3 mmol/L in women or <1.1 in men and waist circumference ≥ 80
                       cm in women or ≥ 90 cm in men). Patients on anti-hypertensive agent for
                       treatment of hypertension or lipid lowering drug for the treatment of
                       hyperlipidaemia will respectively be considered to have one component of the
                       metabolic syndrome.

          4. Subject is capable of giving informed consent prior to the initiation of any study
             related procedures

          5. A female subject of childbearing potential who is sexually active with a
             non-sterilized male partner agrees to use routinely adequate and effective
             contraception to avoid pregnancy during the study period and up to 30 days after the
             final visit.

          6. The subject is able and willing to consistently record food diary to facilitate CGMS
             evaluation.

        Exclusion Criteria:

          1. Subject has received anti-diabetic agents within 6 weeks prior to screening visit.

          2. On dietary supplement known to affect glucose or galactose metabolism.

          3. History of acute cardiovascular disease including myocardial infarction, acute
             coronary syndrome or stroke which required hospitalization in the last 12 months.

          4. Significant renal impairment with estimated glomerular filtration rate (eGFR) <
             60ml/min/1.73m2

          5. Known lactose or galactose intolerance.

          6. History of eating disorder.

          7. Pregnant or lactating female subjects.

          8. Subjects with gastrointestinal disease that may interfere with absorption of the
             investigational product.

          9. Subject has received any investigational product within 30 days of randomization
             visit.

         10. Reduced life expectancy or any condition considered by the investigator as unsuitable
             for enrolment.
      